Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2018

At a glance

  • Drugs Bryostatin-1 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Neurotrope BioScience
  • Most Recent Events

    • 17 Dec 2018 According to a Neurotrope BioScience media release, data are expected during the third quarter of 2019.
    • 13 Aug 2018 According to a Neurotrope BioScience media release, dosing has begun in the study, and completion of the study is anticipated during the third quarter of 2019. The study will be conducted at approximately 30 clinical trial sites.
    • 16 Jul 2018 According to a Neurotrope BioScience media release, the first patient has been enrolled into this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top